Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing

Cancer

Volumn 81, Issue 2, 1997, Pages 89-97

  Sherman, Mark E ^a,b,j   Schiffman, Mark H ^b   Lorincz, Attila T ^c,m   Herrero, Rolando ^d   Hutchinson, Martha L ^e,o   Bratti, Concepcion ^f   Zahniser, David ^g   Morales, Jorge ^h   Hildesheim, Allan ^b   Helgesen, Kay ⁱ   Kelly, Deidra ^j   Alfaro, Mario ^h   Mena, Fernando ^h   Balmaceda, Ileana ^f   Mango, Laurie ^k   Greenberg, Mitchell ^l,n,p  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Digene Corporation   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e TUFTS MEDICAL CENTER   (United States)

^f Ministerio de Salud   (Costa Rica)

^g Cytyc Corporation   (United States)

^h CAJA COSTARRICENSE DE SEGURO SOCIAL   (Costa Rica)

ⁱ INFORMATION MANAGEMENT SERVICES INC   (United States)

^j JOHNS HOPKINS HOSPITAL   (United States)

^k BD Technologies   (United States)

^l GRADUATE HOSPITAL   (United States)

^m Digene Corporation

ⁿ National Testing Laboratories

^o WOMEN AND INFANTS HOSPITAL   (United States)

^p Omnia Corporation   (United States)

more..

Author keywords

Atypical aquamous cells of undetermined significance; Bethesda System; Carcinoma; Cervix; Human papillomavirus; Hybridizalion

Indexed keywords

ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS;

CARCINOMA; COLPOSCOPY; CYTODIAGNOSIS; DNA, VIRAL; FEASIBILITY STUDIES; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0031585924     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970425)81:2<89::AID-CNCR2>3.0.CO;2-9     Document Type: Article

References (31)

1. Broder S. The revised Bethesda System for reporting cervical/vaginal diagnoses: report of the 1991 Bethesda Workshop. JAMA 1994;267:1992.
2. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. JAMA 1994;271:1866-9.
3. Davey DD, Naryshkin S, Nielsen ML, Kline TS. Atypical squamous cells of undetermined significance: interlaboratory comparison and quality assurance monitors. Diagn Cytopathol 1994;4:390-6.
4. Wied GL, Bartels PH, Bibbo M, Gupta PK, Gurley AM, Hilgarth M, et al. Computer-assisted quality assurance. Acta Cytol 1996;40:1-3.
5. Tawa K, Forsythe A, Cove JK, Saltz A, Peters HW, Watring WG. A comparison of the Papanicolaou smear and the Cervigram: sensitivity, specificity, and cost analysis. Obstet Gynecol 1988;71:229-35.
6. Schiffman MH, Sherman ME. HPV testing to improve cervical cancer screening. In: Srivastava S et al., editors. Early detection of cancer: molecular markers. Armonk, NY: Futura Publishing Co., 1994:265-77.
7. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
8. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence that human papillomavirus causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
9. IARC monograph on the evaluation of carcinogenic risk to humans: human papillomaviruses. Volume 64. Lyon, France: IARC, 1995.
10. Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, Kurman RJ, et al. Toward objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994;101:182-7.
11. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Kurman RJ, Hussain M, et al., Human papillomavirus testing by Hybrid Capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
12. Farthing A, Masterson P, Mason WP, Vousden KH. Human papillomavirus detection by Hybrid Capture and its possible clinical use. J Clin Pathol 1994;47:649-52.
13. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high risk HPV types as triage before colposcopy. Am J Obstet Gynecol 1995;172:1150-7.
14. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologie abnormalities. Obstet Gynecol 1995;85:202-10.
15. Richart R. A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol 1990;75:131-2.
16. Aponte-Cipriani SL, Teplitz C, Rorat E, Savino A, Jacobs AJ. Cervical smears prepared by an automated device versus the conventional method: a comparative analysis. Acta Cytol 1995;39:623-30.
17. Bur M, Knowles K, Pekow P, Corral O, Donovan J. Comparison of ThinPrep preparations with conventional cervicovaginal smears: practical considerations. Acta Cytol 1995; 39:631-42.
18. Hutchinson MH, Agarwal P, Denault T, Berger B, Cibas ES. A new look at cervical cytology: ThinPrep multicenter trial results. Acta Cytol 1992;36:499-504.
19. Wilbur DC, Cibas ES, Merritt S, James LP, Berger BM, Bonfiglio TA. ThinPrep processor: clinical trials demonstrate an increased detection rate of abnormal cervical cytologic specimens. Am J Clin Pathol 1994;101:209-14.
20. Herrero R, Schiffman MH, Bratti C, Hildesheim A, Balmaceda I, Sherman ME, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. PAHO J Public Health. In press.
21. Hussain OAN, Butler EB, Nayagam M, Mango L, Alonzo A. An analysis of the variation of human interpretation: PAP-NET a mini-challenge. Anal Cell Pathol 1994;6:157-63.
22. Koss LG, Lin E, Schreiber K, Elgert P, Mango L. Evaluation of the PAPNET cytologic screening system for quality control of cervical smears. Am J Clin Pathol 1994;101:220-9.
23. Sherman ME, Mango LJ, Kelly D, Paull G, Ludin V, Copeland C, et al. PAPNET analysis of reportedly negative smears preceding the diagnosis of a high-grade squamous intraepithelial lesion or carcinoma. Mod Pathol 1994;7:578-81.
24. Schiffman MH, Kiviat NB, Burk RD, Shah KV, Daniel RW, Lews R, et al. Accuracy and reliability of human papillomavirus DNA testing by Hybrid Capture. J Clin Microbiol 1995;33:545-50.
25. Bauer H, Greer C, Manos M. Detection of genital human papillomavirus infection using PCR. In: Herrington CS, McGee JO, editors. Diagnostic molecular pathology: a practical approach. Oxford University Press, 1992:131-52.
26. Manos MM, Ting Y, Wright DK, et al. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In: Furth M, Greaves MF, editors. Molecular diagnostics of human cancer. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1989:209-14.
27. Hildesheim A, Schiffman MH, Gravitt P, Glass AG, Greer C, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women in Portland, Oregon. J Infect Dis 1994;169:235-40.
28. Morell ND, Taylor JR, Snyder RN, Ziel HK, Saltz A, Willie S. False-negative cytology rates in patients in whom invasive cervical cancer subsequently developed. Obstet Gynecol 1982;60:41-5.
29. Gay JD, Donaldson LD, Goellner JR. False-negative results in cervical cytologic studies. Acta Cytol 1985;29:1043-6.
30. Kristensen GB, Skyggebjerg K-D, Holund B, Holm K, Hansen MK. Analysis of cervical smears obtained within three years of the diagnosis of cervical cancer. Acta Cytol 1990;35:47-50.
31. Hall S, Wu TC, Fields A, Sherman ME, Erozan Y. Suitability of ThinPrep specimens for immunocytochemistry and gene amplification by polymerase chain reaction [abstract]. Acta Cytol 1992;35:585.